Arbutus Biopharma Corp Earnings

The next earnings date for Arbutus Biopharma Corp is November 5, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Arbutus Biopharma Corp Earnings

Report Date	Estimated Earnings Per Share
11/05/2025	$-0.03

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Arbutus Biopharma Corp Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
07/31/2025	---	$0	100.00%
04/30/2025	Before Market	$-0.18	-18.08%
02/26/2025	Before Market	---	---
11/06/2024	Before Market	$-0.09	0.00%
08/01/2024	Before Market	$-0.11	-10.00%
05/02/2024	Before Market	$-0.10	9.09%
02/29/2024	Before Market	$-0.12	0.00%
11/07/2023	Before Market	$-0.12	-9.09%
08/03/2023	Before Market	$-0.10	9.09%
05/04/2023	Before Market	$-0.10	28.57%
03/02/2023	Before Market	$-0.14	-7.69%
11/09/2022	Before Market	$-0.12	7.69%
08/04/2022	Before Market	$-0.10	23.08%
05/05/2022	Before Market	$-0.11	31.25%
03/03/2022	Before Market	$-0.15	21.05%
11/04/2021	Before Market	$-0.24	0.00%
08/05/2021	Before Market	$-0.23	-4.55%
05/05/2021	Before Market	$-0.21	8.70%
03/04/2021	Before Market	$-0.23	-4.55%
11/05/2020	Before Market	$-0.27	-22.73%
08/07/2020	Before Market	$-0.25	-4.17%
05/11/2020	Before Market	$-0.25	19.35%
03/05/2020	Before Market	$-0.46	-27.78%
11/06/2019	Before Market	$-1.10	-323.08%
08/05/2019	Before Market	$-0.46	-24.32%
05/06/2019	After Market	$-0.38	-18.75%
03/07/2019	After Market	$-0.37	7.50%
11/07/2018	After Market	$-0.52	-26.83%
08/02/2018	After Market	$-0.44	-10.00%
05/03/2018	After Market	$-0.36	7.69%
03/14/2018	After Market	$-0.90	-130.77%
11/02/2017	After Market	$-0.21	43.24%
08/03/2017	After Market	$-0.33	21.43%
05/04/2017	After Market	$-0.34	12.82%
03/21/2017	Before Market	$-1.48	-300.00%
11/03/2016	After Market	$-0.37	32.73%
08/04/2016	After Market	$-0.75	-92.31%
05/04/2016	After Market	$-0.31	20.51%
03/09/2016	Before Market	$-0.06	85.00%
11/05/2015	After Market	$-0.12	58.62%
08/07/2015	After Market	$-0.20	31.03%
05/06/2015	After Market	$-0.36	0.00%
03/12/2015	After Market	$-0.27	3.57%
11/06/2014	After Market	$-0.39	-25.81%
08/13/2014	---	$-0.54	-107.69%
05/14/2014	---	$-0.22	-195.65%
03/06/2014	---	$-0.15	-400.00%
11/13/2013	---	$-0.40	-100.00%
08/12/2013	After Market	$-0.21	---
05/14/2013	After Market	$-0.18	---
03/27/2013	After Market	$2.70	---
11/13/2012	---	$-0.25	---
08/14/2012	---	$-0.14	12.50%
05/15/2012	---	$-0.25	-47.06%
03/27/2012	---	$-0.15	---
11/08/2011	---	$-0.12	60.00%
08/11/2011	---	$-0.33	-10.00%
05/10/2011	---	$-0.30	16.67%
03/30/2011	---	$-0.20	20.00%
11/15/2010	---	$-1.09	-445.00%
08/12/2010	---	$-0.40	-14.29%
03/17/2010	---	$-0.25	16.67%
08/12/2009	---	$-0.20	-33.33%
05/13/2009	---	$-0.20	20.00%
03/24/2009	---	$-0.35	30.00%
03/30/2008	---	$0.10	100.00%
11/14/2007	---	$0.30	-33.33%
08/08/2007	---	$-1.05	-250.00%

More About Arbutus Biopharma Corp

Website

https://www.arbutusbio.com

Country

USA

Full Time Employees

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

“Arbutus Biopharma Corp Earnings” Can Refer to the Arbutus Biopharma Corp Earnings Date

Some people say “Arbutus Biopharma Corp earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Arbutus Biopharma Corp position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Arbutus Biopharma Corp Stock on the Earnings Date

If you own Arbutus Biopharma Corp stock (ABUS) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Arbutus Biopharma Corp might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Arbutus Biopharma Corp shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Arbutus Biopharma Corp Earnings

You can contact us any time if you would like to ask questions about Arbutus Biopharma Corp earnings or anything else related to the stock market.